BiotechTube
Lynch Biologics

Lynch Biologics

Birmingham, United States· Est.
lynchbiologics.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $3M

Overview

Lynch Biologics is a commercial-stage biotechnology company specializing in growth-factor enhanced matrices for dental and periodontal regenerative surgery. Its core asset, GEM 21S®, is the first and only FDA-approved off-the-shelf source of purified rhPDGF-BB for bone and soft tissue regeneration in oral applications. The company leverages the body's natural healing mechanisms by delivering a key signaling protein to attract stem cells and stimulate angiogenesis. As part of Geistlich, it benefits from an expanded commercial footprint and shared expertise in regenerative solutions.

Dental RegenerationPeriodontal DiseaseOral Surgery

Technology Platform

Recombinant human Platelet-Derived Growth Factor BB (rhPDGF-BB) combined with a beta-tricalcium phosphate (β-TCP) scaffold to actively stimulate chemotaxis, mitogenesis, and angiogenesis for bone and soft tissue regeneration.

Funding History

1
Total raised:$3M
Seed$3M

Opportunities

Leveraging Geistlich's extensive sales and distribution network to significantly expand market penetration for GEM 21S®.
Potential to develop new combination products or formulations by integrating the rhPDGF-BB platform with Geistlich's portfolio of biomaterials.
Growing dental implant and regenerative surgery market creates demand for predictable, advanced biologic solutions.

Risk Factors

Heavy reliance on a single commercial product line creates significant concentration risk.
Faces competition from both standard bone grafts and other biologic approaches, including off-label use of other growth factors.
Market adoption can be limited by cost sensitivity and variable insurance reimbursement in dental procedures.

Competitive Landscape

Operates in the competitive dental bone graft and regenerative materials market, competing against large players like Zimmer Biomet (Bio-Oss), Straumann (Emdogain), Dentsply Sirona, and Osteogenics. Its key differentiation is the purified, off-the-shelf rhPDGF-BB, competing against autologous platelet concentrates (PRF, PRP) which are variable, and other growth factors like BMP-2, which is used off-label in dentistry and has a different safety profile.

More companies in Regenerative Medicine →More companies in United States →